The VAX-31 pneumococcal conjugate vaccine (PCV) candidate met all prespecified primary endpoints in OPUS-1, the pivotal adult phase 3 trial, according to the vaccine’s manufactu ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results